Akebia Therapeutics(AKBA)
icon
搜索文档
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research· 2024-05-09 21:10
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Akebia Th ...
Akebia Therapeutics(AKBA) - 2024 Q1 - Quarterly Report
2024-05-09 19:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION ...
Akebia Therapeutics(AKBA) - 2024 Q1 - Quarterly Results
2024-05-09 19:03
Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9 • Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 • Vafseo launch activities underway with availability expected in January 2025 • Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.—May 9, 2024—Akebia Therape ...
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Prnewswire· 2024-05-02 20:30
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 9, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Regi ...
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
MarketBeat· 2024-04-03 21:11
Key PointsAkebia Therapeutics is a biotech specializing in treatments for chronic kidney diseases (CKD).Its lead drug, Vafseo, received FDA approval for treating anemia in adult CKD patients who have at least 3 months of dialysis.Vafseo is an oral tablet that has been approved in 37 countries.5 stocks we like better than Akebia TherapeuticsAkebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for pat ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prnewswire· 2024-04-03 04:05
公司概况 - Akebia Therapeutics, Inc.(Nasdaq: AKBA)是一家生物制药公司,旨在改善肾脏疾病患者的生活[1] - Akebia Therapeutics成立于2007年,总部位于马萨诸塞州剑桥市[3] 员工期权 - 公司于2024年3月28日向六名新员工授予了购买总计110,000股Akebia普通股的期权,作为这些员工进入公司就业的诱因[1] - 这些期权的行权价格为每股1.83美元,与授予日Akebia普通股的收盘价相等[2] - 期权将在四年内解锁,首年解锁25%的股份,其余75%的股份每季度解锁,前提是新员工继续在Akebia工作[2] - 每个期权有10年期限,受Akebia诱因奖励计划和股票期权协议的条款和条件约束[2]
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Prnewswire· 2024-03-28 08:26
Akebia Therapeutics公司新药Vafseo®批准上市 - Akebia Therapeutics公司宣布美国食品和药物管理局(FDA)已批准Vafseo®(vadadustat)片剂用于治疗患有慢性肾病(CKD)并至少接受三个月透析治疗的成年患者的贫血[1] - Vafseo是一种每日一次口服的缺氧诱导因子脯氨酸羟化酶(HIF-PH)抑制剂,通过激活对缺氧的生理反应来刺激内源性促红细胞生成素的产生,以管理贫血[1] Akebia公司的合作与商业化计划 - Akebia公司致力于为肾病患者提供创新治疗选择,通过与CSL Vifor等行业领先公司合作,计划推出Vafseo以成为成人透析患者的新口服标准治疗[4] - Akebia Therapeutics, Inc.发布了关于Vafseo的商业化计划和前景的前瞻性声明[35] 公司商标和行业数据 - Akebia Therapeutics, Inc.拥有Auryxia®和Vafseo®的注册商标[36] - 美国肾脏数据系统的数据报告显示肾脏疾病在美国的流行病学情况[37]
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Zacks Investment Research· 2024-03-15 06:31
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%.Over the last four quarte ...
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Prnewswire· 2024-03-15 04:15
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass., March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full yea ...
Akebia Therapeutics(AKBA) - 2023 Q4 - Annual Report
2024-03-14 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _to_ Comm ...